Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue 1.4 Market Analysis by Type 1.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Afinitor (Everolimus) 1.4.3 Avastin (Bevacizumab) 1.4.4 Cabomety (Cabozantinib) 1.4.5 Inlyta (Axitinib) 1.4.6 Nexavar (Sorafenib) 1.4.7 Proleukin (Aldesleukin) 1.4.8 Torisel (Temsirolimus) 1.4.9 Sutent (Sunitinib) 1.4.10 Votrient (Pazopanib) 1.5 Market by Application 1.5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2026 1.5.2 Hospitals 1.5.3 Clinic 1.5.4 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2015-2026) 2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Regions 2.2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Share by Regions (2015-2020) 2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Strategy 2.3.6 Primary Interviews with Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Market Size 3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2015-2020) 3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2015-2020) 3.1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio 3.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2019 3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served 3.4 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service 3.5 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2015-2020) 4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2021-2026) 5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application (2015-2026) 5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 6.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in North America (2019-2020) 6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 7 Europe 7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 7.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Europe (2019-2020) 7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 8 China 8.1 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 8.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in China (2019-2020) 8.3 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 8.4 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 9 Japan 9.1 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 9.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Japan (2019-2020) 9.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 9.4 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 10.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 10.4 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 11 India 11.1 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 11.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in India (2019-2020) 11.3 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 11.4 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2015-2020) 12.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Central & South America (2019-2020) 12.3 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) 12.4 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Active Biotech Ab 13.1.1 Active Biotech Ab Company Details 13.1.2 Active Biotech Ab Business Overview and Its Total Revenue 13.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020)) 13.1.5 Active Biotech Ab Recent Development 13.2 Amgen 13.2.1 Amgen Company Details 13.2.2 Amgen Business Overview and Its Total Revenue 13.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.2.5 Amgen Recent Development 13.3 Bayer AG 13.3.1 Bayer AG Company Details 13.3.2 Bayer AG Business Overview and Its Total Revenue 13.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.3.5 Bayer AG Recent Development 13.4 Cipla Limited 13.4.1 Cipla Limited Company Details 13.4.2 Cipla Limited Business Overview and Its Total Revenue 13.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.4.5 Cipla Limited Recent Development 13.5 Roche Holding AG 13.5.1 Roche Holding AG Company Details 13.5.2 Roche Holding AG Business Overview and Its Total Revenue 13.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.5.5 Roche Holding AG Recent Development 13.6 Glaxosmithkline Plc 13.6.1 Glaxosmithkline Plc Company Details 13.6.2 Glaxosmithkline Plc Business Overview and Its Total Revenue 13.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.6.5 Glaxosmithkline Plc Recent Development 13.7 Novartis Ag 13.7.1 Novartis Ag Company Details 13.7.2 Novartis Ag Business Overview and Its Total Revenue 13.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.7.5 Novartis Ag Recent Development 13.8 Pfizer, Inc.  13.8.1 Pfizer, Inc.  Company Details 13.8.2 Pfizer, Inc.  Business Overview and Its Total Revenue 13.8.3 Pfizer, Inc.  Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction 13.8.4 Pfizer, Inc.  Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) 13.8.5 Pfizer, Inc.  Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Market Segments Table 2. Key Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Table 3. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of Afinitor (Everolimus) Table 6. Key Players of Avastin (Bevacizumab) Table 7. Key Players of Cabomety (Cabozantinib) Table 8. Key Players of Inlyta (Axitinib) Table 9. Key Players of Nexavar (Sorafenib) Table 10. Key Players of Proleukin (Aldesleukin) Table 11. Key Players of Torisel (Temsirolimus) Table 12. Key Players of Sutent (Sunitinib) Table 13. Key Players of Votrient (Pazopanib) Table 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 15. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (US$ Million): 2020 VS 2026 Table 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (2015-2020) (US$ Million) Table 17. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2015-2020) Table 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2021-2026) Table 20. Market Top Trends Table 21. Key Drivers: Impact Analysis Table 22. Key Challenges Table 23. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Strategy Table 24. Main Points Interviewed from Key Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players Table 25. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2015-2020) (Million US$) Table 26. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2015-2020) Table 27. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2019) Table 28. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs by Players Market Concentration Ratio (CR5 and HHI) Table 29. Key Players Headquarters and Area Served Table 30. Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service Table 31. Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Table 32. Mergers & Acquisitions, Expansion Plans Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Type (2015-2020) Table 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2021-2026) Table 36. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2015-2020) Table 37. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 38. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Share by Application (2021-2026) Table 39. North America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 40. North America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 41. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 42. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 43. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 44. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 45. Europe Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 46. Europe Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 47. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 48. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 49. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 50. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 51. China Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 52. China Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 53. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 54. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 55. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 56. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 57. Japan Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 58. Japan Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 59. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 60. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 61. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 62. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 63. Southeast Asia Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 64. Southeast Asia Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 65. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 66. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 67. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 68. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 69. India Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 70. India Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 71. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 72. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 73. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 74. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 75. Central & South America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (2019-2020) (Million US$) Table 76. Central & South America Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share (2019-2020) Table 77. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2015-2020) (Million US$) Table 78. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type (2015-2020) Table 79. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2015-2020) (Million US$) Table 80. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2015-2020) Table 81. Active Biotech Ab Company Details Table 82. Active Biotech Ab Business Overview Table 83. Active Biotech Ab Product Table 84. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 85. Active Biotech Ab Recent Development Table 86. Amgen Company Details Table 87. Amgen Business Overview Table 88. Amgen Product Table 89. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 90. Amgen Recent Development Table 91. Bayer AG Company Details Table 92. Bayer AG Business Overview Table 93. Bayer AG Product Table 94. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 95. Bayer AG Recent Development Table 96. Cipla Limited Company Details Table 97. Cipla Limited Business Overview Table 98. Cipla Limited Product Table 99. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 100. Cipla Limited Recent Development Table 101. Roche Holding AG Company Details Table 102. Roche Holding AG Business Overview Table 103. Roche Holding AG Product Table 104. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 105. Roche Holding AG Recent Development Table 106. Glaxosmithkline Plc Company Details Table 107. Glaxosmithkline Plc Business Overview Table 108. Glaxosmithkline Plc Product Table 109. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 110. Glaxosmithkline Plc Recent Development Table 111. Novartis Ag Company Details Table 112. Novartis Ag Business Overview Table 113. Novartis Ag Product Table 114. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 115. Novartis Ag Recent Development Table 116. Pfizer, Inc.  Business Overview Table 117. Pfizer, Inc.  Product Table 118. Pfizer, Inc.  Company Details Table 119. Pfizer, Inc.  Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) (Million US$) Table 120. Pfizer, Inc.  Recent Development Table 121. Research Programs/Design for This Report Table 122. Key Data Information from Secondary Sources Table 123. Key Data Information from Primary Sources List of Figures Figure 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2020 VS 2026 Figure 2. Afinitor (Everolimus) Features Figure 3. Avastin (Bevacizumab) Features Figure 4. Cabomety (Cabozantinib) Features Figure 5. Inlyta (Axitinib) Features Figure 6. Nexavar (Sorafenib) Features Figure 7. Proleukin (Aldesleukin) Features Figure 8. Torisel (Temsirolimus) Features Figure 9. Sutent (Sunitinib) Features Figure 10. Votrient (Pazopanib) Features Figure 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2020 VS 2026 Figure 12. Hospitals Case Studies Figure 13. Clinic Case Studies Figure 14. Others Case Studies Figure 15. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered Figure 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth 2015-2026 (US$ Million) Figure 17. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions: 2020 VS 2026 Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2021-2026) Figure 19. Porter's Five Forces Analysis Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2019 Figure 21. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2019 Figure 22. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2019 Figure 23. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 25. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 26. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 27. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 28. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 29. Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 30. Active Biotech Ab Total Revenue (US$ Million): 2019 Compared with 2018 Figure 31. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 32. Amgen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 33. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 34. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 35. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 36. Cipla Limited Total Revenue (US$ Million): 2019 Compared with 2018 Figure 37. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 38. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018 Figure 39. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 40. Glaxosmithkline Plc Total Revenue (US$ Million): 2019 Compared with 2018 Figure 41. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 42. Novartis Ag Total Revenue (US$ Million): 2019 Compared with 2018 Figure 43. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 44. Pfizer, Inc.  Total Revenue (US$ Million): 2019 Compared with 2018 Figure 45. Pfizer, Inc.  Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2015-2020) Figure 46. Bottom-up and Top-down Approaches for This Report Figure 47. Data Triangulation Figure 48. Key Executives Interviewed

Active Biotech Ab Amgen Bayer AG Cipla Limited Roche Holding AG Glaxosmithkline Plc Novartis Ag Pfizer, Inc.